ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
October 13, 2025

Appointment of Independent Non-Executive Director

Read More
October 07, 2025

TR1 from Lanstead – Major interest in shares

Read More
September 17, 2025

Exercise of Warrants; Total Voting Rights

Read More
September 11, 2025

Exercise of Warrants; Total Voting Rights

Read More
September 01, 2025

Appointments of Chief Scientific Officer and Head of R&D

Read More
September 01, 2025

ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases

Read More
August 20, 2025

TR1 from Lanstead Capital – Major interest in shares

Read More
August 06, 2025

INTERIM RESULTS for the six months ended 30 June 2025

Read More
June 12, 2025

2025 Result of Annual General Meeting

Read More
May 28, 2025

TR1 from Lanstead – Major interest in shares

Read More
May 20, 2025

Notice of AGM and Annual Report & Accounts

Read More
May 19, 2025

FINAL RESULTS for the twelve months ended 31 December 2024

Read More
  • 1
  • 2
  • 3
  • …
  • 24
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved